Barclays’s Telomir Pharmaceuticals TELO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-553
Closed -$708 – 5777
2026
Q2
$708 Buy
+553
New +$720 ﹤0.01% 4962
2026
Q1
– Sell
-2
Closed -$3 – 5519
2025
Q4
$3 Hold
2
– – ﹤0.01% 5174
2025
Q3
$3 Sell
2
-3,015
-100% -$4.55K ﹤0.01% 5427
2025
Q2
$3.77K Sell
3,017
-17,322
-85% -$40K ﹤0.01% 4996
2025
Q1
$65.7K Sell
20,339
-9,620
-32% -$42K ﹤0.01% 4538
2024
Q4
$123K Buy
29,959
+22,941
+327% +$108K ﹤0.01% 4535
2024
Q3
$45.1K Buy
7,018
+5,367
+325% +$26.2K ﹤0.01% 4770
2024
Q2
$7.94K Buy
+1,651
New +$10.3K ﹤0.01% 4533

Other funds holding TELO

Barclays's TELO Position: Q3 2026 in Review

Barclays sold out of Telomir Pharmaceuticals (TELO) in Q3 2026, closing a stake of 553 shares — an estimated $708 sold.

Barclays first reported a position in TELO in Q2 2024 and held it in 8 quarters. The position peaked at $123K in Q4 2024. 23 funds tracked by Wall St. Rank hold TELO as of Q3 2026.

  • Barclays reported no remaining Telomir Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Barclays sold 553 Telomir Pharmaceuticals shares in Q3 2026, an estimated $708.
  • Barclays first reported a position in Telomir Pharmaceuticals in Q2 2024 and held it in 8 quarters.
  • Barclays's Telomir Pharmaceuticals position peaked at $123K in Q4 2024.
  • 23 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.